Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2150 of 4091 results for patient

  1. Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

  2. Naltrexone for the management of opioid dependence (TA115)

    Evidence-based recommendations on naltrexone (Nalorex) for managing opioid dependence in adults.

  3. Neo Pedicle Screw System for spinal fusion surgery (MIB108)

    NICE has developed a medtech innovation briefing (MIB) on the Neo Pedicle Screw System for spinal fusion surgery .

  4. CytoSorb therapy for sepsis (MIB87)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .

  5. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

    In development Reference number: GID-TA11823 Expected publication date: TBC

  6. Falloposcopy with coaxial catheter (HTG35)

    Evidence-based recommendations on falloposcopy with coaxial catheter. This involves using a small camera passed through a narrow tube to look inside a woman’s fallopian tubes and see if there are any problems that may be affecting her ability to become pregnant.

  7. Speaking engagements

    Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country

  8. Contraceptive services for under 25s (PH51)

    This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.

  9. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  10. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG737)

    Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.

  11. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

    Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.

  12. Spasticity in under 19s: management (CG145)

    This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.

  13. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

  14. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  15. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MIB210)

    NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .

  16. NICE health technology evaluation topic selection: the manual (PMG37)

    This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance

  17. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)

    NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .

  18. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

  19. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

  20. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

  21. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  22. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence

  23. Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)

    Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.

  24. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  25. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (HTG460)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a device under the skin of the chest, which detects and treats fast heartbeats called tachyarrhythmias.

  26. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

  27. Radiofrequency ablation of hepatocellular carcinoma (HTG1)

    Evidence-based recommendations on radiofrequency ablation of hepatocellular carcinoma. This involves using heat to destroy the part of the liver that contains the cancer.

  28. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

  29. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

  30. The PediGuard for placing pedicle screws in spinal surgery (MIB26)

    NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery

  31. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

  32. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

  33. Multiple technology appraisal (MTA) process timeline

    These are the main stages in the multiple technology appraisal process used before April 2018.

  34. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  35. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  36. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

  37. Balloon dilation for chronic eustachian tube dysfunction (HTG534)

    Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children. This involves using a balloon filled with saline to widen the eustachian tube.

  38. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

  39. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

  40. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  41. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

  42. Life sciences: how to get your product to market

    NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.

  43. Your role as a NICE committee member

    From GPs, nurses and social workers, to pharmacists, physiotherapists and patients, your voice has the power to transform care across...

  44. Your role as a NICE committee member

    From GPs, nurses and social workers, to pharmacists, physiotherapists and patients, your voice has the power to transform care across...

  45. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

    Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.

  46. Medicines and prescribing

    Support for delivering quality, safety and efficiency in the optimisation of medicines.

  47. Getting involved as a voluntary and community sector organisation

    Getting involved with NICE as a voluntary and community sector organisation

  48. Digital health

    We assess the value of digital health technologies that offer the greatest potential to improve health and wellbeing.

  49. Getting involved as a voluntary and community sector organisation

    Getting involved with NICE as a voluntary and community sector organisation

  50. Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (HTG654)

    Evidence-based recommendations on laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. This involves placing a ring of beads outside of the food pipe, just above the stomach. Magnets inside the beads hold them together to keep the food pipe closed but are weak enough to move apart to allow food or liquid to be swallowed. The aim is to prevent acid reflux.